Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study

[1]  Reed J. D. Sorensen,et al.  Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis , 2023, The Lancet.

[2]  S. Ganesan,et al.  Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE—An Observational Study , 2022, Frontiers in Public Health.

[3]  Andrew T. Levin,et al.  COVID-19 prevalence and mortality in longer-term care facilities , 2022, European Journal of Epidemiology.

[4]  P. Landete,et al.  Evolution and Clinical Trend of SARS-CoV-2 Variants , 2022, Open Respiratory Archives.

[5]  G. Brady,et al.  Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents , 2022, Journal of the American Medical Directors Association.

[6]  G. Lippi,et al.  Efficacy of COVID-19 vaccine booster doses in older people , 2021, European Geriatric Medicine.

[7]  M. Ruiz-García,et al.  Clinical performance of a standardized SARS-CoV-2 interferon-γ release assay for simple detection of T-cell responses after infection or vaccination , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  H. Zar,et al.  Towards a population-based threshold of protection for COVID-19 vaccines , 2021, Vaccine.

[9]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[10]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[11]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.

[12]  L. Abu-Raddad,et al.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[13]  M. Quezada-Feijoo,et al.  Mortality risk factors in a Spanish cohort of oldest-old patients hospitalized with COVID-19 in an acute geriatric unit: the OCTA-COVID study , 2021, European Geriatric Medicine.

[14]  A. Hayward,et al.  Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 , 2021, The Lancet.

[15]  Frances E. Muldoon,et al.  Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.

[16]  J. Vekemans,et al.  Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[17]  J. Parienti,et al.  Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study , 2021, Vaccine.

[18]  C. Robertson,et al.  Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study , 2021, BMJ.

[19]  H. Kunugi,et al.  Approaches to Nutritional Screening in Patients with Coronavirus Disease 2019 (COVID-19) , 2021, International journal of environmental research and public health.

[20]  Yvette N. Lamb.  BNT162b2 mRNA COVID-19 Vaccine: First Approval , 2021, Drugs.

[21]  M. Andrew,et al.  Age and frailty in COVID-19 vaccine development , 2020, The Lancet.

[22]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[23]  E. Thomson,et al.  Efficacy and safety of COVID-19 vaccines in older people , 2020, Age and ageing.

[24]  J. Ouslander,et al.  Coronavirus Disease 2019 in Geriatrics and Long‐Term Care: The ABCDs of COVID‐19 , 2020, Journal of the American Geriatrics Society.

[25]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.